Filing identity and reporting period
Important entity mismatch: The supplied filing is AVROBIO, Inc.’s Form 10-K for the fiscal year ended December 31, 2021, filed March 17, 2022. It is not a filing for Tectonic Therapeutic, Inc. This summary describes AVROBIO’s filing. The filing reports annual results, not separate 2021 fourth-quarter results.
AVROBIO was a clinical-stage gene therapy company developing ex vivo lentiviral therapies for rare diseases. It reported no product revenue and had five programs in its pipeline at year-end; two were in clinical development.
Financial results and liquidity
| Metric | 2021 | 2020 |
|---|---|---|
| Revenue | No product revenue | No product revenue |
| Research and development expense | $83.1 million | $87.2 million |
| General and administrative expense | $35.7 million | $33.0 million |
| Total operating expenses | $118.8 million | $120.2 million |
| Net loss | $119.1 million | $119.7 million |
| Basic and diluted loss per share | $2.78 | $3.31 |
| Cash used in operating activities | $98.0 million | $98.8 million |
At December 31, 2021, cash and cash equivalents were $189.6 million, down from $259.7 million a year earlier. Total assets were $203.8 million; total liabilities were $34.4 million, including $14.9 million of note payable, net of discount. Stockholders’ equity was $169.5 million. No profit margin is meaningful because the company had no product revenue.
Management estimated existing cash would fund operating expenses and capital expenditure requirements into the first quarter of 2024, subject to substantial uncertainty and spending assumptions. The company reported an accumulated deficit of $383.5 million.
Changes and material developments
- Net loss narrowed by $0.6 million year over year; operating expenses declined $1.4 million. Lower R&D spending, including the absence of a $8.0 million one-time Hunter-program license fee recorded in 2020, was partly offset by higher personnel costs. G&A rose mainly due to stock-based compensation and personnel costs.
- Operating cash use was nearly unchanged, while financing cash inflow fell to $30.4 million from $172.6 million in 2020, when the company completed two follow-on offerings.
- In November 2021, AVROBIO drew $15.0 million under a secured term loan. The loan bears interest at the greater of prime plus 4.85% or 8.10%, has interest-only payments through November 2024, and matures October 2026. It includes a 9% end-of-term charge and collateral over substantially all assets other than intellectual property.
- In January 2022, after year-end, the company deprioritized AVR-RD-01 for Fabry disease and stopped enrollment in its Phase 2 trial following variable engraftment data in five recently dosed patients. It also announced a workforce reduction of approximately 23%, with estimated severance costs of about $2.5 million, expected to be recorded in Q1 2022.
Outlook, programs, and risks
- Management planned to continue cystinosis and Gaucher type 1 development, pursue regulatory discussions for Gaucher type 3 and Pompe, and expected a collaborator-sponsored Hunter syndrome Phase 1/2 trial to begin in 2023. It expected to provide interim Gaucher type 1 data in 2022. These are forward-looking plans, not assured outcomes.
- As of March 1, 2022, four patients had been dosed in the collaborator-sponsored cystinosis study and three in the company-sponsored Gaucher type 1 study. Cystinosis interim findings and both programs’ safety and efficacy data were preliminary and subject to change.
- Fabry deprioritization eliminated access to $20 million of milestone-contingent loan funding. A further $15 million tranche required lender consent; the filing cautions that availability is not assured.
- Key risks include continued losses and need for additional capital; clinical, regulatory, manufacturing and patient-enrollment uncertainty; possible adverse effects from gene therapy or conditioning; dependence on sole-source suppliers and contract manufacturers; COVID-19 disruption; loan covenants and repayment obligations; competition and reimbursement uncertainty; and intellectual-property and licensing risks.
- The company reported no material pending or threatened legal proceedings. Management concluded disclosure controls and internal control over financial reporting were effective at a reasonable assurance level; the auditor did not attest to internal-control effectiveness because of the company’s emerging-growth-company status. The financial statements received an unqualified audit opinion.
Important facts for investors to verify
- Confirm the intended issuer: this source is AVROBIO, Inc., not Tectonic Therapeutic, Inc.
- Review the complete audited statements and debt agreement, including borrowing conditions, lender-consent requirements, covenants, interest and end-of-term charges.
- Track cash burn, spending after the Fabry program reduction, and whether the stated cash runway remains achievable.
- Assess updated clinical data, especially durability of engraftment, safety, and comparability of the different manufacturing and vector processes.
- Verify the timing, enrollment, regulatory path and funding requirements for the remaining pipeline programs, and the effect of the workforce reduction and severance costs.